Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose YTX-7739 study in healthy adults and Parkinson's disease participants
NL-OMON55131Recruiting
- Sponsor
- Yumanity Therapeutics
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of YTX-7739 in Parkinson's disease (PD) (2 arms), sponsored by Yumanity Therapeutics. Primary endpoints: Safety and tolerability and Pharmacokinetics of YTX-7739. Started Sep 2020; status: recruiting.
02
Drugs
YTX-7739
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON55131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55131.